These results suggest that SLURP1, LY6D, WFDC1, NOV, and GSTM3 are closely associated with the development of bladder cancer and have value as potential therapeutic targets, warranting further functional validation and clinical research. This evidence concerns the gene SLURP1 and urinary bladder cancer.